Close
Nordic 9Nordic 9

UCB Ventures (investor - Corporate Investor)

Belgium ucbventures.com
See something wrong or missing? Let us know
Offices:Bruxelles

UCB Ventures is a €150 million strategic corporate venture fund established in 2017 by the Belgian pharma group UCB

Average round investment:53.94M USD
Average number per year:1.2
Distribution: 2025 (1)2023 (1)2022 (2)2021 (1)2020 (1)
Portfolio companies: Spain Splice BioUnited Kingdom ViaNautisBelgium Bingli See the entire list
Mostly invests in: Belgium Belgium (3) Health services (6)
See the entire list

Showing 3 of 6 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to UCB Ventures

Name Criteria
United Kingdom Perscitus LLP
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Software Services
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Japan Rakuten Capital
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: Spain
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
United Kingdom Isomer Capital
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: Belgium, United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
United Kingdom Kathaka
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Wheatsheaf Group
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Software Services
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.5
  • Active last 12 months: Yes
Netherlands Flow ventures NL
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.7
  • Active last 12 months: Yes
United States New Science Ventures
91%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Software Services
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: Belgium, United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
Japan Sumitomo Corporation
91%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Manufacturing, Software Services
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United Kingdom Cassandra Stavrou
91%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: United Kingdom
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
Ireland Tom Stafford
91%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B, B2C (Retail)
  • Common investees countries: United Kingdom, Spain
  • Average number of deals per year: 2.1
  • Active last 12 months: Yes
Top